ConvaTec stock gains analyst support despite Berenberg price target cut

Published on 09/11/2026 at 16:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ConvaTec stock closed at 218.40 pence on September 11, 2026, about 15.8 percent below its 52-week high of 259.30 pence. Berenberg Bank cut its price target to 335 pence on September 11, 2026, but kept a buy rating, implying more than 50 percent upside.

Moderne Medizintechnik-Reinraumfertigung mit Technikern an steriler Produktionslinie — ConvaTec Group Plc GB00BD3VFW73 zeigt moderne Medizintechnik-Fertigung mit sterilen Produktionslinien und Reinraumtechnikern, Illustration mit AI erstellt.

ConvaTec Group stock (ISIN GB00BD3VFW73) ended London trading at 218.40 pence on September 11, 2026, valuing the medical products specialist at about GBP 4.24 billion and leaving the shares notably below their recent 52-week high of 259.30 pence.MarketBeat reported on September 11, 2026, that Berenberg Bank trimmed its price target on ConvaTec to 335 pence but maintained a buy rating, highlighting significant potential upside from the current level.

Analyst moves underpin ConvaTec stock story

According to MarketBeat on September 11, 2026, Berenberg Bank lowered its price objective for ConvaTec Group from 340 pence to 335 pence while reiterating a buy recommendation on the shares.

The revised Berenberg target of 335 pence still implies an upside of 53.39 percent from the company’s previous close, illustrating that the brokerage continues to see meaningful appreciation potential despite the modest target reduction.MarketBeat also notes that consensus across eight analysts stands at a Moderate Buy rating, with an average target price of 305.44 pence.

That average target of 305.44 pence sits roughly 87 pence above the current 218.40 pence share price, pointing to approximately 39.8 percent expected upside and underlining that Berenberg’s view is somewhat more optimistic than the broader analyst community.MarketBeat reports that eight analysts currently rate the stock Buy and one rates it Hold.

Valuation, balance sheet and trading ranges

As detailed by MarketBeat, ConvaTec Group shares opened at 218.40 pence on September 11, 2026, on the London Stock Exchange, giving the company a market capitalization of around GBP 4.24 billion.

The same data show that the stock has traded between a 52-week low of 193 pence and a 52-week high of 259.30 pence, meaning the current level sits about 13.2 percent above the low and 15.8 percent below the high, leaving room for recovery if fundamentals and sentiment stay supportive.MarketBeat also cites a price-to-earnings ratio of 35.23, a P/E/G ratio of 0.93 and a beta of 0.77, suggesting moderate valuation and below-market volatility.

The company’s balance sheet metrics in the same overview show a debt-to-equity ratio of 121.83, a current ratio of 1.93 and a quick ratio of 0.96, indicating that ConvaTec uses leverage but retains reasonable short-term liquidity.MarketBeat also highlights that the shares trade around their 50-day moving average of 224.13 pence and close to the 200-day moving average of 220.95 pence, underscoring a relatively tight trading band in recent months.

Business focus and medium-term drivers

ConvaTec Group PLC develops, manufactures and sells medical products, services and technologies across Europe, North America and other international markets, giving investors exposure to diversified healthcare demand.MarketBeat describes the business as focusing on advanced wound dressings and skin care products that address chronic wounds linked to conditions such as diabetes, as well as acute wounds from traumatic injury and burns.

The company also offers ostomy care solutions, including devices, accessories and services for patients with a stoma following colorectal cancer, inflammatory bowel disease or bladder cancer, positioning ConvaTec in segments with structural demand tied to aging populations and chronic disease prevalence.MarketBeat notes that corporate insiders hold about 0.98 percent of the company, following transactions such as the purchase of 50,000 shares at 226 pence by insider Tobias Hestler in August 2026.

For investors, the key medium-term question is how effectively ConvaTec can translate this product positioning into sustained revenue and earnings growth, given the current valuation multiple and the leverage shown in its debt-to-equity ratio. Analyst targets clustered between roughly 270 pence and 315 pence, as mentioned in historical research references, suggest that the market expects continued operational progress, even if Berenberg’s latest move slightly trims the most optimistic end of the range.MarketBeat

ConvaTec stock price snapshot

ConvaTec stock last closed at 218.40 pence on the London Stock Exchange on September 11, 2026, with the shares trading within a 52-week range of 193 pence to 259.30 pence and implying a market capitalization of about GBP 4.24 billion at that level.